Green Cross, aRigen under joint research to combat superbacteria
Published: 2011-01-26 06:56:00
Updated: 2011-01-26 06:56:00
Green Cross Corp. said Friday that it has signed an exclusive license with aRigen Pharmaceuticals in Japan to develop and commercialize WAP-8294A2 (Lotilibcin), a first-line anti-MRSA (methicillin-resistant Staphylococcus aureus) product candidate, possibly in 2016 in Korea.
The agreement betw...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
